Compare · FRMM vs NVO
FRMM vs NVO
Side-by-side comparison of Forum Markets Incorporated (FRMM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRMM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 2773.9x FRMM ($77.7M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for FRMM).
- NVO has more recent analyst coverage (25 ratings vs 1 for FRMM).
- Company
- Forum Markets Incorporated
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $77.7M
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 6
- 9
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FRMM
- Forum Markets Incorporated filed SEC Form 8-K: Leadership Update
- Forum Markets Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Sidoti Events, LLC's August Micro-Cap Virtual Conference
- Chief Executive Officer Rudisill Mcandrew covered exercise/tax liability with 98,174 shares, decreasing direct ownership by 5% to 1,786,805 units (SEC Form 4) (for withholding tax)
- SEC Form 10-Q filed by Forum Markets Incorporated
- Forum Markets Reports Second Quarter 2026 Financial Results
- Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Forum Announces Second Quarter 2026 Earnings Release Date and Webcast Details
- Large owner Lomashuk Konstantin sold $1,500,000 worth of shares (250,000 units at $6.00) (SEC Form 4)
- Forum Markets to Present Company Strategy and Business Model at Force Family Office Investor Webinar
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S